| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Katherine L Nathanson | Q37369859 |
| Keiran S M Smalley | Q61525717 | ||
| Keith Flaherty | Q6384357 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3241-3244 | |
| P577 | publication date | 2009-04-07 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Genetic subgrouping of melanoma reveals new opportunities for targeted therapy | |
| P478 | volume | 69 |
| Q56898613 | Q56898613 |
| Q27851611 | A Variant in a MicroRNA complementary site in the 3' UTR of the KIT oncogene increases risk of acral melanoma |
| Q34259205 | A brief history of melanoma: from mummies to mutations |
| Q37815139 | A new era: melanoma genetics and therapeutics |
| Q28817145 | A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner |
| Q34986199 | Adjuvant Immunotherapy and Radiation in the Management of High-risk Resected Melanoma. |
| Q41360812 | Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells |
| Q34217755 | Canine malignant melanoma alpha-3 integrin binding peptides |
| Q64007381 | Carbazole Derivatives' Binding to c-KIT G-Quadruplex DNA |
| Q27349020 | Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors |
| Q94564084 | Comprehensive Genomic Profiling of Rare Tumors: Routes to Targeted Therapies |
| Q39712781 | Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. |
| Q34020065 | Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma |
| Q34104555 | Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers |
| Q42785249 | G-quadruplex-binding benzo[a]phenoxazines down-regulate c-KIT expression in human gastric carcinoma cells |
| Q38500731 | Inflammatory signaling compromises cell responses to interferon alpha |
| Q28475549 | Integrated ligand-receptor bioinformatic and in vitro functional analysis identifies active TGFA/EGFR signaling loop in papillary thyroid carcinomas |
| Q40009179 | Management of melanoma brain metastases in the era of targeted therapy |
| Q37727077 | Measurement of constitutive MAPK and PI3K/AKT signaling activity in human cancer cell lines |
| Q37605787 | Melanoma biomarkers: current status and utility in diagnosis, prognosis, and response to therapy |
| Q24606438 | PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells |
| Q37799845 | PLX4032: does it keep its promise for metastatic melanoma treatment? |
| Q34761941 | PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression |
| Q35320304 | Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma |
| Q37863222 | Preparing pathology for personalized medicine: possibilities for improvement of the pre-analytical phase. |
| Q54497681 | Sinonasal mucosal melanoma: Molecular profile and therapeutic implications from a series of 32 cases. |
| Q37873463 | State of the art of diagnostic technology for early-stage melanoma |
| Q37245787 | The Conundrum of Genetic "Drivers" in Benign Conditions |
| Q35878248 | The current state of targeted therapy in melanoma: this time it's personal |
| Q37731451 | The glutamate release inhibitor Riluzole decreases migration, invasion, and proliferation of melanoma cells |
| Q38337903 | Towards the lean lab: the industry challenge |
| Q34802932 | Tumor heterogeneity and strategies to overcome kinase inhibitor resistance in cancer: lessons from melanoma |
| Q82623062 | [Advances in molecular biology and their application in the diagnosis and treatment of melanoma] |
| Q39719008 | c-Abl and Arg are activated in human primary melanomas, promote melanoma cell invasion via distinct pathways, and drive metastatic progression |
Search more.